Artivion (NYSE:AORT) announced today that it received FDA premarket approval (PMA) for its AMDS Hybrid Prosthesis device. The approval covers acute Debakey Type 1 aortic dissections with either clinical or radiographic malperfusion. Atlanta-based Artivion estimates that this population comprises approximately 60% of all Debakey Type 1 aortic … [Read more...] about Artivion earns FDA nod for aortic arch prosthesis device
Artivion
Artivion closes $175M acquisition of aortic arch maker Endospan
Endospan announced today that Artivion completed its $175 million acquisition of the company, following FDA approval for its Nexus system. The FDA granted premarket approval (PMA) for the Nexus aortic arch system last month. Nexus treats aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. … [Read more...] about Artivion closes $175M acquisition of aortic arch maker Endospan
